Inactive Instrument

ALPHANCO VEN Share Price

Equities

AVC.P

CA02079V1031

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Dynamic Chart
Alphanco Venture Corp. has Changed its Name to Marvel Biosciences Corp CI
Marvel Biosciences Corp. Appoints J. Roderick Matheson as Chief Executive Officer CI
Marvel Biosciences Corp. Appoints Preston J. Maddin as Chief Financial Officer CI
Marvel Biosciences Corp. Announces Management Appointments CI
Marvel Biotechnology Inc. completed the acquisition of Alphanco Venture Corp. (TSXV:AVC.P) for CAD 3.8 million in a reverse merger transaction. CI
Alphanco Venture Corp. Reports Earnings Results for the Third Quarter Ended April 30, 2021 CI
Alphanco Venture Corp. Reports Earnings Results for the Second Quarter Ended January 31, 2021 CI
Marvel Biotechnology Inc. entered into a binding letter agreement to acquire Alphanco Venture Corp. (TSXV:AVC.P) in a reverse merger transaction. CI
Alphanco Venture Corp. Reports Earnings Results for the Full Year Ended July 31, 2020 CI
Alphanco Venture Corp. Reports Earnings Results for the Third Quarter Ended April 30, 2020 CI
Alphanco Venture Corp. Reports Earnings Results for the Second Quarter Ended January 31, 2020 CI
Alphanco Venture Corp. Reports Earnings Results for the First Quarter Ended October 31, 2019 CI
Alphanco Venture Corp. Reports Earnings Results for the Full Year Ended July 31, 2019 CI
Alphanco Venture Corp. Reports Earnings Results for the Third Quarter Ended April 30, 2019 CI
Alphanco Venture Corp. Reports Earnings Results for the Second Quarter Ended January 31, 2019 CI
More news
Marvel Biosciences Corp, formerly Alphanco Venture Corp, is a Canada-based life sciences company. The Company is focused on discovery and the development of pharmaceutical products for the treatment of neurologically associated diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder ADHD, and addiction), cancer, and application to the non-neurological disease of non-alcoholic steatohepatitis liver fibrosis. The Company also intends to advance compound 1b (MB-204) into Phase 1 clinical trials for neurological diseases.
Sector
-
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW